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Background: Non ST elevation myocardial infarction (NSTEMI) is one of the most common manifestations of acute coronary syndromes. The 
purpose of this study was to evaluate the prognostic role of cardiac troponin I (cTnI) at presentation, peak cardiac troponin I and b-type natriuretic 
peptide (BNP) in patients with NSTEMI
methods: We consecutively enrolled 190 (30 female) (mean age 66±13 years) subjects presenting in our department with NSTEMI. All subjects 
were treated according to guidelines and they were follow-up for one year. cTnI and BNP at presentation, peak value of cTnI, left ventricle ejection 
fraction (EF) and basic demographic characteristic were recorded. The primary end point was defined as cardiovascular death, readmission to 
hospital with heart failure, and new acute coronary syndrome.
results: During the follow-up period the primary end point occurred in 49 subjects (26%). The subjects who present the primary end point had 
significantly increased values of logBNP (2.50±0.67 pg/ml vs 1.95±0.65 pg/ml, p<0.001) and peak logcTnI (0.93±0.65 ng/L vs 0.61±0.61 
ng/L, p=0.002) compared to subjects free of cardiovascular events. Nevertheless, logcTnI at presentation did not differ between subjects who 
presented the primary end point and those free of events (-0.04±0.90ng/L vs. -0.16±0.80ng/L, p=0.39). Multivariate Cox regression analysis after 
incorporating potential confounders such as age, gender, EF, smoking habits and the presence of diabetes mellitus, hyperlipidemia, and hypertension 
revealed that for every increase in BNP for 100pg/ml there is a 4.5% anticipate increase in the relative risk to present the primary end point 
(HR=1.045, 95%CI 1.016 to 1.076, p=0.002) and for every increase in peak cTnI for 10ng/L there is a 11% anticipate increase in the relative risk to 
present the primary end point (HR=1.11, 95%CI 1.02 to 1.21, p=0.02). Moreover cTnI at presentation does not contribute significant to the outcome 
of subjects presented with NSTEMI.
conclusion: These results documented the prognostic significance of BNP and cTnI in patients presented with NSTEMI and highlight the 
importance of peak cTnI compared to cTnI at presentation.
